Base de dados : MEDLINE
Pesquisa : D06.472.317.400 [Categoria DeCS]
Referências encontradas : 2325 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 233 ir para página                         

  1 / 2325 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29216250
[Au] Autor:Choi YY; Noh SH; An JY
[Ad] Endereço:Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.
[Ti] Título:A randomized controlled trial of Roux-en-Y gastrojejunostomy vs. gastroduodenostomy with respect to the improvement of type 2 diabetes mellitus after distal gastrectomy in gastric cancer patients.
[So] Source:PLoS One;12(12):e0188904, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The purpose of this study is to compare the effect of diabetes control induced by Roux-en-Y gastrojejunostomy(RY) vs Billroth-I reconstruction(BI) after distal gastrectomy in patients with early gastric cancer(EGC) and type 2 diabetes(T2DM). Forty EGC patients with T2DM, aged 20-80 years, who were expected to undergo curative distal gastrectomy were randomized 1:1 to RY(n = 20) or BI(n = 20). Diabetes medication status, biochemical and hormonal data including blood glucose, HbA1c, insulin, C-peptide, HOMA-IR, ghrelin, leptin, GLP-1, PYY, and GIP were evaluated for 12 months after surgery. Although pre- and postoperative 12-month fasting and postprandial glucose levels did not show a significant difference, HbA1c, C-peptide, and HOMA-IR levels were significantly improved at 12 months after surgery in both BI and RY groups. Sixty percent of RY patients and 20% of BI patients decreased their medication satisfying FBS<126 mg/dL and HbA1c<6.5% and 5% of BI patients stopped their medication satisfying the criteria of FBS<126 mg/dL and HbA1c<6.0%. The improvement patterns were more sustainable with less fluctuation in RY than in BI. On hormonal analysis, ghrelin and leptin levels were decreased and PYY and GIP levels were increased at 12 months after surgery in both groups without significant difference according to the reconstruction type and diabetic improvement status except ghrelin. In gastric cancer surgery, RY reconstruction showed better and more durable diabetes control compared to BI during the first year after surgery. Gastric cancer surgery led to decreased ghrelin and leptin and increased PYY and GIP, which might have a role in improving insulin resistance and glucose homeostasis.
[Mh] Termos MeSH primário: Diabetes Mellitus Tipo 2/cirurgia
Duodeno/cirurgia
Derivação Gástrica/métodos
Neoplasias Gástricas/cirurgia
Estômago/cirurgia
[Mh] Termos MeSH secundário: Idoso
Diabetes Mellitus Tipo 2/complicações
Feminino
Polipeptídeo Inibidor Gástrico/sangue
Grelina/sangue
Peptídeo 1 Semelhante ao Glucagon/sangue
Seres Humanos
Leptina/sangue
Masculino
Meia-Idade
Peptídeo YY/sangue
Estudos Prospectivos
Neoplasias Gástricas/complicações
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Ghrelin); 0 (Leptin); 106388-42-5 (Peptide YY); 59392-49-3 (Gastric Inhibitory Polypeptide); 89750-14-1 (Glucagon-Like Peptide 1)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171226
[Lr] Data última revisão:
171226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171208
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0188904


  2 / 2325 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28893239
[Au] Autor:You H; Zhang T; Feng W; Gai Y
[Ad] Endereço:Seventh People's Hospital of Shanghai University of TCM, No.358 Datong Road, Gaoqiao Town, Pudong New District, Shanghai, 200137, China.
[Ti] Título:Association of TCM body constitution with insulin resistance and risk of diabetes in impaired glucose regulation patients.
[So] Source:BMC Complement Altern Med;17(1):459, 2017 Sep 11.
[Is] ISSN:1472-6882
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Impaired glucose regulation (IGR) patients have increased risk of type 2 diabetes mellitus (T2DM). Identifying relevant risk factors in IGR subjects could facilitate early detection and prevention of IGR progression to diabetes. This study investigated the association between Traditional Chinese Medicine (TCM) body constitution and serum cytokines, and whether body constitution could independently predict diabetes in IGR subjects. METHOD: Patients with IGR (n = 306) received a blood test and their body constitution type was assessed using a body constitution questionnaire (BCQ). Serum levels of cytokines were measured by ELISA. Patients were followed up for at least three years, and their status of diabetes were recorded. Multivariate logistic regression was used to estimate odds ratios (ORs) of diabetes for body constitution. RESULTS: Phlegm-damp, Damp-heat and Qi-deficiency were three most common unbanlenced constitutions among IGR subjects. Phlegm-damp and Damp-heat constitution subjects showed higher serum levels of interleukin 6 (IL-6), tumour necrosis factor-α (TNF-α), leptin and lower serum levels of adiponectin (P<0.05). Qi-deficiency constitution subjects showed higher serum levels of leptin and lower serum levels of adiponectin, glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) (P<0.05). Subjects with Phlegm-damp or Damp-heat constitution demonstrated a significantly higher risk of diabetes (P<0.05). CONCLUSION: Phlegm-damp and Damp-heat TCM body constitution are strongly associated with abnormal serum cytokines, and could potentially serve as a predictor of diabetes in IGR subjects. Body constitution can help to identify IGR subjects who are at a high risk of progression to diabetes.
[Mh] Termos MeSH primário: Diabetes Mellitus Tipo 2/metabolismo
Diabetes Mellitus Tipo 2/fisiopatologia
Resistência à Insulina/fisiologia
Medicina Tradicional Chinesa
[Mh] Termos MeSH secundário: Adiponectina/sangue
Citocinas/sangue
Feminino
Polipeptídeo Inibidor Gástrico/sangue
Peptídeo 1 Semelhante ao Glucagon/sangue
Seres Humanos
Leptina/sangue
Masculino
Meia-Idade
Estudos Prospectivos
Inquéritos e Questionários
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adiponectin); 0 (Cytokines); 0 (Leptin); 59392-49-3 (Gastric Inhibitory Polypeptide); 89750-14-1 (Glucagon-Like Peptide 1)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170918
[Lr] Data última revisão:
170918
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170913
[St] Status:MEDLINE
[do] DOI:10.1186/s12906-017-1964-0


  3 / 2325 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28875871
[Au] Autor:Ojo B; Simenson AJ; O'Hara C; Wu L; Gou X; Peterson SK; Lin D; Smith BJ; Lucas EA
[Ad] Endereço:Nutritional Sciences Department,Oklahoma State University,Stillwater,OK 74078,USA.
[Ti] Título:Wheat germ supplementation alleviates insulin resistance and cardiac mitochondrial dysfunction in an animal model of diet-induced obesity.
[So] Source:Br J Nutr;118(4):241-249, 2017 Aug.
[Is] ISSN:1475-2662
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Obesity is strongly associated with insulin resistance (IR), along with mitochondrial dysfunction to metabolically active tissues and increased production of reactive O2 species (ROS). Foods rich in antioxidants such as wheat germ (WG), protect tissues from damage due to ROS and modulate some negative effects of obesity. This study examined the effects of WG supplementation on markers of IR, mitochondrial substrate metabolism and innate antioxidant markers in two metabolically active tissues (i.e. liver and heart) of C57BL/6 mice fed a high-fat-high-sucrose (HFS) diet. Male C57BL/6 mice, 6-week-old, were randomised into four dietary treatment groups (n 12 mice/group): control (C, 10 % fat kcal), C+10 % WG, HFS (60 % fat kcal) or HFS+10 % WG (HFS+WG). After 12 weeks of treatment, HFS+WG mice had significantly less visceral fat (-16 %, P=0·006) compared with the HFS group. WG significantly reduced serum insulin (P=0·009), the insulinotropic hormone, gastric inhibitory peptide (P=0·0003), and the surrogate measure of IR, homoeostatic model assessment of IR (P=0·006). HFS diet significantly elevated (45 %, P=0·02) cardiac complex 2 mitochondrial VO2, suggesting increased metabolic stress, whereas WG stabilised this effect to the level of control. Consequently, genes which mediate antioxidant defense and mitochondrial biogenesis (superoxide dismutase 2 (Sod2) and PPARγ coactivator 1-α (Pgc1a), respectively) were significantly reduced (P<0·05) in the heart of the HFS group, whereas WG supplementation tended to up-regulate both genes. WG significantly increased hepatic gene expression of Sod2 (P=0·048) but not Pgc1a. Together, these results showed that WG supplementation in HFS diet, reduced IR and improved cardiac mitochondrial metabolic functions.
[Mh] Termos MeSH primário: Suplementos Nutricionais
Coração/efeitos dos fármacos
Resistência à Insulina
Fígado/efeitos dos fármacos
Mitocôndrias/efeitos dos fármacos
Obesidade/complicações
Triticum
[Mh] Termos MeSH secundário: Animais
Antioxidantes/metabolismo
Antioxidantes/farmacologia
Antioxidantes/uso terapêutico
Dieta Hiperlipídica
Modelos Animais de Doenças
Polipeptídeo Inibidor Gástrico/sangue
Expressão Gênica/efeitos dos fármacos
Insulina/sangue
Gordura Intra-Abdominal/metabolismo
Fígado/metabolismo
Masculino
Camundongos Endogâmicos C57BL
Mitocôndrias/metabolismo
Miocárdio/metabolismo
Obesidade/tratamento farmacológico
Obesidade/etiologia
Obesidade/metabolismo
Estresse Oxidativo/efeitos dos fármacos
Coativador 1-alfa do Receptor gama Ativado por Proliferador de Peroxissomo/genética
Coativador 1-alfa do Receptor gama Ativado por Proliferador de Peroxissomo/metabolismo
Preparações de Plantas/farmacologia
Preparações de Plantas/uso terapêutico
Espécies Reativas de Oxigênio
Superóxido Dismutase/genética
Superóxido Dismutase/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antioxidants); 0 (Insulin); 0 (Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha); 0 (Plant Preparations); 0 (Ppargc1a protein, mouse); 0 (Reactive Oxygen Species); 59392-49-3 (Gastric Inhibitory Polypeptide); EC 1.15.1.1 (Superoxide Dismutase); EC 1.15.1.1 (superoxide dismutase 2)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170919
[Lr] Data última revisão:
170919
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170907
[St] Status:MEDLINE
[do] DOI:10.1017/S0007114517002082


  4 / 2325 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28803984
[Au] Autor:Hira T; Koga T; Sasaki K; Hara H
[Ad] Endereço:Research Faculty of Agriculture, Hokkaido University, Sapporo, Japan; Graduate School of Agriculture, Hokkaido University, Sapporo, Japan. Electronic address: hira@chem.agr.hokudai.ac.jp.
[Ti] Título:Canagliflozin potentiates GLP-1 secretion and lowers the peak of GIP secretion in rats fed a high-fat high-sucrose diet.
[So] Source:Biochem Biophys Res Commun;492(2):161-165, 2017 Oct 14.
[Is] ISSN:1090-2104
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The glucose-induced secretion of incretins, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), is dependent on luminal glucose levels and transport of glucose via the sodium-glucose transporter 1 (SGLT1) in the small intestine. Because GLP-1 and GIP function in decreasing and increasing the body weight, respectively, we aimed to analyze the effect of transient inhibition of SGLT1 by canagliflozin on incretin secretion in an obese rat model. Male Sprague-Dawley rats were maintained on a high-fat high-sucrose diet for 6-7 weeks, and plasma GLP-1 and GIP levels were measured during an oral glucose tolerance test (OGTT). In addition, GLP-1 secretion was examined in a murine GLP-1 producing enteroendocrine cell line, GLUTag. Concomitant administration of 10 mg/kg canagliflozin with glucose loading suppressed glucose excursion, increased total GLP-1 levels, and reduced total GIP levels in systemic circulation, as revealed in the OGTT. Total and active GLP-1 levels were increased in portal blood, whereas total and active GIP levels tended to be decreased 15 min after the administration of canagliflozin with glucose. Canagliflozin (at 0.1-30 µM) did not directly affect release of GLP-1 in vitro. These results suggest that the oral administration of canagliflozin suppresses GIP secretion via the inhibition of SGLT1 in the upper part of the intestine and enhances GLP-1 secretion by increasing the glucose delivery to the lower part of the small intestine in an obese rodent model.
[Mh] Termos MeSH primário: Canagliflozina/farmacologia
Polipeptídeo Inibidor Gástrico/metabolismo
Peptídeo 1 Semelhante ao Glucagon/metabolismo
Hipoglicemiantes/farmacologia
Obesidade/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Glicemia/metabolismo
Canagliflozina/uso terapêutico
Linhagem Celular
Dieta Hiperlipídica/efeitos adversos
Carboidratos da Dieta/efeitos adversos
Polipeptídeo Inibidor Gástrico/sangue
Peptídeo 1 Semelhante ao Glucagon/sangue
Glucose/metabolismo
Hipoglicemiantes/uso terapêutico
Incretinas/sangue
Incretinas/metabolismo
Insulina/sangue
Insulina/metabolismo
Masculino
Obesidade/sangue
Obesidade/etiologia
Obesidade/metabolismo
Ratos
Ratos Sprague-Dawley
Transportador 1 de Glucose-Sódio/antagonistas & inibidores
Transportador 1 de Glucose-Sódio/metabolismo
Sacarose/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Blood Glucose); 0 (Dietary Carbohydrates); 0 (Hypoglycemic Agents); 0 (Incretins); 0 (Insulin); 0 (Sodium-Glucose Transporter 1); 0SAC974Z85 (Canagliflozin); 57-50-1 (Sucrose); 59392-49-3 (Gastric Inhibitory Polypeptide); 89750-14-1 (Glucagon-Like Peptide 1); IY9XDZ35W2 (Glucose)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170925
[Lr] Data última revisão:
170925
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170815
[St] Status:MEDLINE


  5 / 2325 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28667118
[Au] Autor:Asmar M; Asmar A; Simonsen L; Gasbjerg LS; Sparre-Ulrich AH; Rosenkilde MM; Hartmann B; Dela F; Holst JJ; Bülow J
[Ad] Endereço:Department of Endocrinology, Bispebjerg University Hospital, Copenhagen, Denmark masmar@sund.ku.dk.
[Ti] Título:The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor.
[So] Source:Diabetes;66(9):2363-2371, 2017 Sep.
[Is] ISSN:1939-327X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A truncated form of human glucose-dependent insulinotropic polypeptide (GIP), GIP(3-30)NH , was recently identified as an antagonist of the human GIP receptor. This study examined the ability of GIP(3-30)NH to antagonize the physiological actions of GIP in glucose metabolism, subcutaneous abdominal adipose tissue blood flow (ATBF), and lipid metabolism in humans. Eight lean subjects were studied by measuring arteriovenous concentrations of metabolites and ATBF on three different occasions during hyperglycemic-hyperinsulinemic clamps with concomitant infusions of GIP, GIP(3-30)NH , or both GIP and GIP(3-30)NH During infusion of GIP(3-30)NH alone and in combination with GIP, insulin levels and the total glucose amount infused to maintain the clamp were lower than during GIP alone. In addition, ATBF remained constant during the antagonist and increased only slightly in combination with GIP, whereas it increased fivefold during GIP alone. Adipose tissue triacylglyceride (TAG) and glucose uptake decreased, and the free fatty acid/glycerol ratio increased during the antagonist alone and in combination with GIP. The changes in glucose infusion rates and plasma insulin levels demonstrate an inhibitory effect of the antagonist on the incretin effect of GIP. In addition, the antagonist inhibited GIP-induced increase in ATBF and decreased the adipose tissue TAG uptake, indicating that GIP also plays a crucial role in lipid metabolism.
[Mh] Termos MeSH primário: Polipeptídeo Inibidor Gástrico/metabolismo
Glucose/metabolismo
Metabolismo dos Lipídeos/efeitos dos fármacos
Receptores dos Hormônios Gastrointestinais/metabolismo
[Mh] Termos MeSH secundário: Tecido Adiposo/irrigação sanguínea
Adulto
Glicemia/efeitos dos fármacos
Estudos Cross-Over
Ácidos Graxos não Esterificados
Polipeptídeo Inibidor Gástrico/genética
Técnica Clamp de Glucose
Glicerol
Seres Humanos
Masculino
Fragmentos de Peptídeos
Triglicerídeos/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Blood Glucose); 0 (Fatty Acids, Nonesterified); 0 (Peptide Fragments); 0 (Receptors, Gastrointestinal Hormone); 0 (Triglycerides); 0 (gastric inhibitory polypeptide (3-30)-amide); 0 (gastric inhibitory polypeptide receptor); 59392-49-3 (Gastric Inhibitory Polypeptide); IY9XDZ35W2 (Glucose); PDC6A3C0OX (Glycerol)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171017
[Lr] Data última revisão:
171017
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170702
[St] Status:MEDLINE
[do] DOI:10.2337/db17-0480


  6 / 2325 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28655715
[Au] Autor:Chia CW; Carlson OD; Liu DD; González-Mariscal I; Santa-Cruz Calvo S; Egan JM
[Ad] Endereço:Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, Maryland chiac@mail.nih.gov.
[Ti] Título:Incretin secretion in humans is under the influence of cannabinoid receptors.
[So] Source:Am J Physiol Endocrinol Metab;313(3):E359-E366, 2017 Sep 01.
[Is] ISSN:1522-1555
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The mechanisms regulating incretin secretion are not fully known. Human obesity is associated with altered incretin secretion and elevated endocannabinoid levels. Since cannabinoid receptors (CBRs) are expressed on incretin-secreting cells in rodents, we hypothesized that endocannabinoids are involved in the regulation of incretin secretion. We compared plasma glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) responses during oral glucose tolerance test (OGTT) in 20 lean and 20 obese participants from the Baltimore Longitudinal Study of Aging (BLSA). Next, we recruited 20 healthy men to evaluate GIP and GLP-1 responses during OGTT after administering placebo or nabilone (CBR agonist) in a randomized, double-blind, crossover fashion. Compared with the BLSA lean group, the BLSA obese group had significantly higher fasting and post-OGTT GIP levels, but similar fasting GLP-1 and significantly lower post-OGTT GLP-1 levels. In the nabilone vs. placebo study, when compared with placebo, nabilone resulted in significantly elevated post-dose fasting GIP levels and post-OGTT GIP levels, but no change in post-dose fasting GLP-1 levels together with significantly lower post-OGTT GLP-1 levels. Glucose levels were not different with both interventions. We conclude that elevated GIP levels in obesity are likely a consequence of increased endocannabinoid levels. CBRs exert tonic control over GIP secretion, which may have a homeostatic effect in suppressing GLP-1 secretion. This raises the possibility that gut hormones are influenced by endocannabinoids.
[Mh] Termos MeSH primário: Agonistas de Receptores de Canabinoides/farmacologia
Dronabinol/análogos & derivados
Polipeptídeo Inibidor Gástrico/efeitos dos fármacos
Peptídeo 1 Semelhante ao Glucagon/efeitos dos fármacos
Obesidade/metabolismo
Receptores de Canabinoides/metabolismo
[Mh] Termos MeSH secundário: Adulto
Glicemia/metabolismo
Estudos de Casos e Controles
Estudos Cross-Over
Método Duplo-Cego
Dronabinol/farmacologia
Feminino
Polipeptídeo Inibidor Gástrico/sangue
Polipeptídeo Inibidor Gástrico/secreção
Peptídeo 1 Semelhante ao Glucagon/sangue
Peptídeo 1 Semelhante ao Glucagon/secreção
Teste de Tolerância a Glucose
Seres Humanos
Incretinas/sangue
Incretinas/secreção
Estudos Longitudinais
Masculino
Meia-Idade
Estudos Prospectivos
Receptores de Canabinoides/efeitos dos fármacos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Blood Glucose); 0 (Cannabinoid Receptor Agonists); 0 (Incretins); 0 (Receptors, Cannabinoid); 2N4O9L084N (nabilone); 59392-49-3 (Gastric Inhibitory Polypeptide); 7J8897W37S (Dronabinol); 89750-14-1 (Glucagon-Like Peptide 1)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170629
[St] Status:MEDLINE
[do] DOI:10.1152/ajpendo.00080.2017


  7 / 2325 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28630069
[Au] Autor:Ohara-Nemoto Y; Nakasato M; Shimoyama Y; Baba TT; Kobayakawa T; Ono T; Yaegashi T; Kimura S; Nemoto TK
[Ad] Endereço:Department of Oral Molecular Biology, Course of Medical and Dental Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan ynemoto@nagasaki-u.ac.jp.
[Ti] Título:Degradation of Incretins and Modulation of Blood Glucose Levels by Periodontopathic Bacterial Dipeptidyl Peptidase 4.
[So] Source:Infect Immun;85(9), 2017 Sep.
[Is] ISSN:1098-5522
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Severe periodontitis is known to aggravate diabetes mellitus, though molecular events related to that link have not been fully elucidated. , a major pathogen of periodontitis, expresses dipeptidyl peptidase 4 (DPP4), which is involved in regulation of blood glucose levels by cleaving incretins in humans. We examined the enzymatic characteristics of DPP4 from as well as two other periodontopathic bacteria, and , and determined whether it is capable of regulating blood glucose levels. Cell-associated DPP4 activity was found in those microorganisms, which was effectively suppressed by inhibitors of human DPP4, and molecules sized 73 kDa in , and 71 kDa in and were immunologically detected. The / values of recombinant DPP4s ranged from 721 ± 55 to 1,283 ± 23 µM s toward Gly-Pro-4-methylcoumaryl-7-amide (MCA), while those were much lower for His-Ala-MCA. Matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) analysis showed His/Tyr-Ala dipeptide release from the N termini of incretins, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide, respectively, with the action of microbial DPP4. Moreover, intravenous injection of DPP4 into mice decreased plasma active GLP-1 and insulin levels, accompanied by a substantial elevation in blood glucose over the control after oral glucose administration. These results are the first to show that periodontopathic bacterial DPP4 is capable of modulating blood glucose levels the same as mammalian DPP4; thus, the incidence of periodontopathic bacteremia may exacerbate diabetes mellitus via molecular events of bacterial DPP4 activities.
[Mh] Termos MeSH primário: Glicemia
Dipeptidil Peptidase 4/metabolismo
Incretinas/metabolismo
Porphyromonas gingivalis/enzimologia
Prevotella intermedia/enzimologia
Tannerella forsythia/enzimologia
[Mh] Termos MeSH secundário: Animais
Dipeptidil Peptidase 4/genética
Feminino
Polipeptídeo Inibidor Gástrico/metabolismo
Peptídeo 1 Semelhante ao Glucagon/metabolismo
Insulina/sangue
Camundongos Endogâmicos C57BL
Proteólise
Proteínas Recombinantes/genética
Proteínas Recombinantes/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Blood Glucose); 0 (Incretins); 0 (Insulin); 0 (Recombinant Proteins); 59392-49-3 (Gastric Inhibitory Polypeptide); 89750-14-1 (Glucagon-Like Peptide 1); EC 3.4.14.5 (Dipeptidyl Peptidase 4)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170621
[St] Status:MEDLINE


  8 / 2325 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28610922
[Au] Autor:NamKoong C; Kim MS; Jang BT; Lee YH; Cho YM; Choi HJ
[Ad] Endereço:Functional Neuroanatomy of Metabolism Regulation Laboratory, Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea; BK21Plus Biomedical Science Project, Seoul National University College of Medicine, Seoul, Republic of Korea; Neuroscience Research
[Ti] Título:Central administration of GLP-1 and GIP decreases feeding in mice.
[So] Source:Biochem Biophys Res Commun;490(2):247-252, 2017 Aug 19.
[Is] ISSN:1090-2104
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Glucagon-like peptide-1 amide (GLP-1) and gastric inhibitory polypeptide (GIP) are incretin hormones regulating energy metabolism. GLP-1 and GIP combination is suggested as a promising therapeutic strategy for treatment of obesity and diabetes. However, the neuronal mechanisms are not yet investigated. In the present study, we investigated the role of central GLP-1 and GIP in regulation of body weight homeostasis. The effect of GLP-1 with GIP on food intake, body weight, locomotor activity were determined following intracerebroventricular (ICV) administration of GLP-1 and/or GIP in mice. ICV administration of low dose GLP-1 (0.3 nmol) and GIP (1 and 3 nmol) did not change food intake. However, ICV administration of higher doses GLP-1 (1 and 3 nmol) and GIP (6 nmol) significantly decreased food intake and body weight. To investigate the synergic effect of ICV GLP-1 and GIP, subeffective dose GLP-1 (0.3 nmol) and subeffective dose GIP (1 nmol) were chosen for further co-administration study. ICV co-administration of GLP-1 and GIP significantly decreased food intake, body weight and drinking. ICV co-administration of GLP-1 and GIP significantly increased neuronal activation and pro-opiomelanocortin (POMC) expression in hypothalamic arcuate nucleus. The neuronal activation and POMC expression were observed in two distinct neuronal populations. These results provide neuronal mechanisms supporting the development of GLP-1 and GIP combination therapeutics for treatment of obesity and diabetes.
[Mh] Termos MeSH primário: Ingestão de Alimentos/efeitos dos fármacos
Polipeptídeo Inibidor Gástrico/administração & dosagem
Polipeptídeo Inibidor Gástrico/farmacologia
Peptídeo 1 Semelhante ao Glucagon/administração & dosagem
Peptídeo 1 Semelhante ao Glucagon/farmacologia
[Mh] Termos MeSH secundário: Animais
Infusões Intraventriculares
Masculino
Camundongos
Camundongos Endogâmicos C57BL
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
59392-49-3 (Gastric Inhibitory Polypeptide); 89750-14-1 (Glucagon-Like Peptide 1)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170926
[Lr] Data última revisão:
170926
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170615
[St] Status:MEDLINE


  9 / 2325 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28566533
[Au] Autor:Chondronikola M; Porter C; Malagaris I; Nella AA; Sidossis LS
[Ad] Endereço:Metabolism UnitShriners Hospitals for Children-Galveston, Galveston, Texas, USA.
[Ti] Título:Brown adipose tissue is associated with systemic concentrations of peptides secreted from the gastrointestinal system and involved in appetite regulation.
[So] Source:Eur J Endocrinol;177(1):33-40, 2017 Jul.
[Is] ISSN:1479-683X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Brown adipose tissue (BAT) has been proposed as a potential therapeutic target against obesity and its related metabolic conditions. Data from studies in rodents support a cross talk between BAT and other distal tissues. The relation between BAT and peptide hormones secreted from the gastrointestinal system (GI) and involved in appetite regulation is not known in humans. DESIGN: We studied 18 men during thermoneutral conditions and mild non-shivering cold exposure (CE). METHODS: 2-Deoxy-2-( F)fluoro-d-glucose positron emission tomography-computed tomography scans were conducted after mild cold to measure BAT volume. Fasting serum concentration of GI-secreted peptides and peptides involved in appetite regulation were measured during thermoneutral conditions and mild CE. RESULTS: During thermoneutral conditions, BAT volume was associated with lower serum concentration of leptin ( = 0.006), gastric inhibitory polypeptide ( = 0.016) and glucagon ( = 0.048) after adjusting for age and body fat percent. CE significantly decreased serum leptin ( = 0.004) and glucagon concentration ( = 0.020), while cold-induced BAT activation was significantly associated with lower serum ghrelin concentration ( = 0.029). CONCLUSIONS: BAT is associated with systemic concentrations of GI-secreted peptides and peptides involved in appetite regulation, suggesting a potential cross talk between BAT and the enteropancreatic axis. Further studies are needed to elucidate the potential link of BAT with the postprandial levels of appetite-regulating peptides and the putative role of BAT in appetite regulation in humans.
[Mh] Termos MeSH primário: Tecido Adiposo Marrom/metabolismo
Tecido Adiposo Marrom/fisiologia
Regulação do Apetite/fisiologia
Trato Gastrointestinal/metabolismo
Trato Gastrointestinal/fisiologia
Neuropeptídeos/metabolismo
Neuropeptídeos/fisiologia
[Mh] Termos MeSH secundário: Tecido Adiposo Marrom/diagnóstico por imagem
Adiposidade
Adulto
Idoso
Envelhecimento/metabolismo
Composição Corporal
Temperatura Baixa
Fluordesoxiglucose F18
Polipeptídeo Inibidor Gástrico/sangue
Polipeptídeo Inibidor Gástrico/metabolismo
Grelina/sangue
Glucagon/sangue
Glucagon/metabolismo
Seres Humanos
Leptina/sangue
Leptina/metabolismo
Masculino
Meia-Idade
Tomografia por Emissão de Pósitrons
Compostos Radiofarmacêuticos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Ghrelin); 0 (Leptin); 0 (Neuropeptides); 0 (Radiopharmaceuticals); 0Z5B2CJX4D (Fluorodeoxyglucose F18); 59392-49-3 (Gastric Inhibitory Polypeptide); 9007-92-5 (Glucagon)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170914
[Lr] Data última revisão:
170914
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170602
[St] Status:MEDLINE
[do] DOI:10.1530/EJE-16-0958


  10 / 2325 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28493909
[Au] Autor:St-Jean M; Boudreau F; Carpentier AC; Hivert MF
[Ad] Endereço:Department of Medicine, University of Sherbrooke, Sherbrooke, Quebec, Canada.
[Ti] Título:HNF1α defect influences post-prandial lipid regulation.
[So] Source:PLoS One;12(5):e0177110, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Hepatocyte nuclear factor 1 alpha (HNF1α) defects cause Mature Onset Diabetes of the Young type 3 (MODY3), characterized by defects in beta-cell insulin secretion. However, HNF1α is involved in many other metabolic pathways with relevance for monogenic or polygenic type 2 diabetes. We aimed to investigate gut hormones, lipids, and insulin regulation in response to a meal test in HNF1α defect carriers (MODY3) compared to non-diabetic subjects (controls) and type 2 diabetes (T2D). METHODS: We administered a standardized liquid meal to each participant. Over 6 hours, we measured post-meal responses of insulin regulation (blood glucose, c-peptide, insulin), gut hormones (ghrelin, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1) and lipids (non-esterified fatty acids [NEFA] and triglycerides). RESULTS: We found that MODY3 participants had lower insulin secretion indices than controls and T2D participants, showing the expected ß-cell defect. MODY3 had similar glycated hemoglobin levels (HbA1c median [IQR]: 6.5 [5.6-7.6]%) compared to T2D (median: 6.6 [6.2-6.9]%; P<0.05). MODY3 had greater insulin sensitivity (Matsuda index: 71.9 [29.6; 125.5]) than T2D (3.2 [4.0; 6.0]; P<0.05). MODY3 experienced a larger decrease in the ratio of NEFA to insulin (NEFA 30-0 / insulin 30-0: -39 [-78; -30] x104) in the early post-prandial period (0-30 minutes) compared to controls and to T2D (-2.0 [-0.6; -6.4] x104; P<0.05). MODY3 had lower fasting (0.66 [0.46; 1.2] mM) and post-meal triglycerides levels compared to T2D (fasting: 2.3 [1.7; 2.7] mM; P<0.05). We did not detect significant post-meal differences in ghrelin and incretins between MODY3 and other groups. CONCLUSION: In response to a standard meal test, MODY3 showed greater early post-prandial NEFA diminution in response to relatively low early insulin secretion, and they maintained very low post-prandial triglycerides levels.
[Mh] Termos MeSH primário: Fator 1-alfa Nuclear de Hepatócito/metabolismo
Insulina/metabolismo
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Glicemia/metabolismo
Peptídeo C/sangue
Peptídeo C/metabolismo
Criança
Diabetes Mellitus Tipo 2/sangue
Diabetes Mellitus Tipo 2/genética
Diabetes Mellitus Tipo 2/metabolismo
Ácidos Graxos não Esterificados/sangue
Ácidos Graxos não Esterificados/metabolismo
Feminino
Polipeptídeo Inibidor Gástrico/sangue
Polipeptídeo Inibidor Gástrico/metabolismo
Grelina/sangue
Grelina/metabolismo
Peptídeo 1 Semelhante ao Glucagon/sangue
Peptídeo 1 Semelhante ao Glucagon/metabolismo
Fator 1-alfa Nuclear de Hepatócito/genética
Seres Humanos
Insulina/genética
Masculino
Meia-Idade
Período Pós-Prandial
Triglicerídeos/sangue
Triglicerídeos/metabolismo
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Blood Glucose); 0 (C-Peptide); 0 (Fatty Acids, Nonesterified); 0 (Ghrelin); 0 (Hepatocyte Nuclear Factor 1-alpha); 0 (Insulin); 0 (Triglycerides); 59392-49-3 (Gastric Inhibitory Polypeptide); 89750-14-1 (Glucagon-Like Peptide 1)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170911
[Lr] Data última revisão:
170911
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170512
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0177110



página 1 de 233 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde